Oncolytics Biotech Inc. (ONCY)
USD 0.55
(0.0%)
USD 0.55
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -31.11 Million CAD | -175.49% |
| 2022 | -11.29 Million CAD | 72.19% |
| 2021 | -40.6 Million CAD | -31.77% |
| 2020 | -30.81 Million CAD | -125.91% |
| 2019 | -13.64 Million CAD | 0.42% |
| 2018 | -13.69 Million CAD | -15.75% |
| 2017 | -11.83 Million CAD | 1.65% |
| 2016 | -12.03 Million CAD | 49.89% |
| 2015 | -24.01 Million CAD | -69.69% |
| 2014 | -14.15 Million CAD | 43.88% |
| 2013 | -25.22 Million CAD | -30.52% |
| 2012 | -19.32 Million CAD | 41.3% |
| 2011 | -32.91 Million CAD | 16.23% |
| 2010 | -39.29 Million CAD | -15.66% |
| 2009 | -33.97 Million CAD | -357.31% |
| 2008 | -7.42 Million CAD | -10.64% |
| 2007 | -6.71 Million CAD | -100.96% |
| 2006 | -3.34 Million CAD | 0.59% |
| 2005 | -3.36 Million CAD | 72.58% |
| 2004 | -12.25 Million CAD | -392.09% |
| 2003 | -2.49 Million CAD | 69.51% |
| 2002 | -8.16 Million CAD | 44.88% |
| 2001 | -14.82 Million CAD | 15.16% |
| 2000 | -17.46 Million CAD | -297.1% |
| 1999 | -4.39 Million CAD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -21.17 Million CAD | 9.09% |
| 2024 Q1 | -26.1 Million CAD | 16.08% |
| 2023 Q2 | -17.04 Million CAD | -11.34% |
| 2023 Q1 | -15.3 Million USD | -35.53% |
| 2023 FY | -31.11 Million CAD | -175.49% |
| 2023 Q3 | -39.46 Million CAD | -131.6% |
| 2023 Q4 | -31.11 Million CAD | 21.17% |
| 2022 FY | -11.29 Million CAD | 72.19% |
| 2022 Q2 | -33.16 Million CAD | 14.74% |
| 2022 Q4 | -11.29 Million CAD | 64.6% |
| 2022 Q3 | -31.9 Million CAD | 3.82% |
| 2022 Q1 | -38.89 Million CAD | 4.21% |
| 2021 FY | -40.6 Million CAD | -31.77% |
| 2021 Q3 | -47.37 Million CAD | 5.35% |
| 2021 Q1 | -49.73 Million CAD | -61.39% |
| 2021 Q4 | -40.6 Million CAD | 14.29% |
| 2021 Q2 | -50.05 Million CAD | -0.64% |
| 2020 Q2 | -29.58 Million CAD | 1.81% |
| 2020 FY | -30.81 Million CAD | -125.91% |
| 2020 Q4 | -30.81 Million CAD | -17.65% |
| 2020 Q1 | -30.13 Million CAD | -120.87% |
| 2020 Q3 | -26.19 Million CAD | 11.46% |
| 2019 Q2 | -11.58 Million CAD | 13.76% |
| 2019 Q4 | -13.64 Million CAD | -16.65% |
| 2019 Q3 | -11.69 Million CAD | -0.94% |
| 2019 FY | -13.64 Million CAD | 0.42% |
| 2019 Q1 | -13.43 Million CAD | 1.93% |
| 2018 Q1 | -7.74 Million CAD | 34.56% |
| 2018 Q4 | -13.69 Million CAD | 15.51% |
| 2018 FY | -13.69 Million CAD | -15.75% |
| 2018 Q3 | -16.21 Million CAD | 13.48% |
| 2018 Q2 | -18.74 Million CAD | -141.97% |
| 2017 FY | -11.83 Million CAD | 1.65% |
| 2017 Q3 | -14.03 Million CAD | 15.85% |
| 2017 Q4 | -11.83 Million CAD | 15.66% |
| 2017 Q1 | -10.1 Million CAD | 16.05% |
| 2017 Q2 | -16.67 Million CAD | -65.07% |
| 2016 Q4 | -12.03 Million CAD | 22.92% |
| 2016 Q2 | -18.32 Million CAD | 9.45% |
| 2016 FY | -12.03 Million CAD | 49.89% |
| 2016 Q3 | -15.61 Million CAD | 14.78% |
| 2016 Q1 | -20.23 Million CAD | 15.75% |
| 2015 Q2 | -30.01 Million CAD | -5.04% |
| 2015 Q4 | -24.01 Million CAD | 14.11% |
| 2015 Q3 | -27.96 Million CAD | 6.85% |
| 2015 Q1 | -28.57 Million CAD | -101.92% |
| 2015 FY | -24.01 Million CAD | -69.69% |
| 2014 Q3 | -15.01 Million CAD | 11.06% |
| 2014 Q4 | -14.15 Million CAD | 5.73% |
| 2014 FY | -14.15 Million CAD | 43.88% |
| 2014 Q1 | -20.15 Million CAD | 20.08% |
| 2014 Q2 | -16.88 Million CAD | 16.25% |
| 2013 Q1 | -41.51 Million CAD | -114.87% |
| 2013 Q2 | -36.15 Million CAD | 12.92% |
| 2013 Q4 | -25.22 Million CAD | 14.43% |
| 2013 FY | -25.22 Million CAD | -30.52% |
| 2013 Q3 | -29.47 Million CAD | 18.48% |
| 2012 Q1 | -44.62 Million CAD | -35.55% |
| 2012 FY | -19.32 Million CAD | 41.3% |
| 2012 Q4 | -19.32 Million CAD | 25.7% |
| 2012 Q3 | -26 Million CAD | 23.06% |
| 2012 Q2 | -33.8 Million CAD | 24.25% |
| 2011 Q1 | -49.91 Million CAD | -27.02% |
| 2011 FY | -32.91 Million CAD | 16.23% |
| 2011 Q2 | -46.64 Million CAD | 6.56% |
| 2011 Q3 | -40.24 Million CAD | 13.72% |
| 2011 Q4 | -32.91 Million CAD | 18.2% |
| 2010 Q1 | -27.14 Million CAD | 16.35% |
| 2010 FY | -39.29 Million CAD | -15.66% |
| 2010 Q4 | -39.29 Million CAD | -144.11% |
| 2010 Q3 | -16.09 Million CAD | 30.63% |
| 2010 Q2 | -23.2 Million CAD | 14.51% |
| 2009 Q1 | -7.36 Million CAD | 0.85% |
| 2009 Q4 | -32.44 Million CAD | -236.09% |
| 2009 FY | -33.97 Million CAD | -357.31% |
| 2009 Q3 | -9.65 Million CAD | 19.43% |
| 2009 Q2 | -11.98 Million CAD | -62.67% |
| 2008 Q4 | -7.42 Million CAD | 41.41% |
| 2008 FY | -7.42 Million CAD | -10.64% |
| 2008 Q3 | -12.68 Million CAD | -55.03% |
| 2008 Q2 | -8.17 Million CAD | -11.64% |
| 2008 Q1 | -7.32 Million CAD | -9.11% |
| 2007 Q4 | -6.71 Million CAD | -101.87% |
| 2007 Q2 | -6.92 Million CAD | 38.86% |
| 2007 FY | -6.71 Million CAD | -100.96% |
| 2007 Q3 | -3.32 Million CAD | 51.96% |
| 2007 Q1 | -11.32 Million CAD | -238.93% |
| 2006 FY | -3.34 Million CAD | 0.59% |
| 2006 Q2 | -7.07 Million CAD | -12.43% |
| 2006 Q3 | -3.8 Million CAD | 46.18% |
| 2006 Q4 | -3.34 Million CAD | 12.23% |
| 2006 Q1 | -6.29 Million CAD | -87.2% |
| 2005 Q4 | -3.36 Million CAD | 25.65% |
| 2005 Q1 | -8.31 Million CAD | 32.18% |
| 2005 Q2 | -7.76 Million CAD | 6.64% |
| 2005 Q3 | -4.52 Million CAD | 41.75% |
| 2005 FY | -3.36 Million CAD | 72.58% |
| 2004 Q4 | -12.25 Million CAD | -421.44% |
| 2004 Q2 | -2.9 Million CAD | -4.21% |
| 2004 Q3 | -2.35 Million CAD | 19.18% |
| 2004 FY | -12.25 Million CAD | -392.09% |
| 2004 Q1 | -2.79 Million CAD | -12.05% |
| 2003 Q4 | -2.49 Million CAD | 32.0% |
| 2003 FY | -2.49 Million CAD | 69.51% |
| 2003 Q1 | -6.73 Million CAD | 17.53% |
| 2003 Q2 | -13.33 Million CAD | -97.94% |
| 2003 Q3 | -3.66 Million CAD | 72.53% |
| 2002 Q1 | -11.86 Million CAD | 19.92% |
| 2002 Q2 | -9.81 Million CAD | 17.31% |
| 2002 Q3 | -7.58 Million CAD | 22.72% |
| 2002 FY | -8.16 Million CAD | 44.88% |
| 2002 Q4 | -8.16 Million CAD | -7.71% |
| 2001 Q1 | -16.95 Million CAD | 2.94% |
| 2001 Q4 | -14.82 Million CAD | 5.65% |
| 2001 Q3 | -15.7 Million CAD | 4.71% |
| 2001 FY | -14.82 Million CAD | 15.16% |
| 2001 Q2 | -16.48 Million CAD | 2.77% |
| 2000 Q4 | -17.46 Million CAD | 6.14% |
| 2000 Q3 | -18.61 Million CAD | -9.38% |
| 2000 Q2 | -17.01 Million CAD | 2.31% |
| 2000 Q1 | -17.41 Million CAD | 0.0% |
| 2000 FY | -17.46 Million CAD | -297.1% |
| 1999 FY | -4.39 Million CAD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Absci Corporation | -72.59 Million USD | 57.146% |
| Adaptive Biotechnologies Corporation | 164.36 Million USD | 118.928% |
| Alnylam Pharmaceuticals, Inc. | 1.86 Billion USD | 101.664% |
| Alzamend Neuro, Inc. | -75.33 Thousand USD | -41197.422% |
| Apollomics, Inc. | -27.39 Million USD | -13.565% |
| 180 Life Sciences Corp. | -655.73 Thousand USD | -4644.483% |
| Atossa Therapeutics, Inc. | -88.46 Million USD | 64.83% |
| Bicycle Therapeutics plc | -481.46 Million USD | 93.538% |
| Barinthus Biotherapeutics plc | -129.11 Million USD | 75.904% |
| BioXcel Therapeutics, Inc. | 36.16 Million USD | 186.03% |
| CASI Pharmaceuticals, Inc. | 4.15 Million USD | 848.58% |
| Chimerix, Inc. | -25.51 Million USD | -21.923% |
| CRISPR Therapeutics AG | -150.84 Million USD | 79.376% |
| Contineum Therapeutics, Inc. Class A Common Stock | 177.66 Million USD | 117.511% |
| EyePoint Pharmaceuticals, Inc. | -275.79 Million USD | 88.719% |
| Fortress Biotech, Inc. | 7.66 Million USD | 505.884% |
| Fortress Biotech, Inc. | 7.66 Million USD | 505.884% |
| Gritstone bio, Inc. | 39.49 Million USD | 178.782% |
| Allakos Inc. | -24.97 Million USD | -24.569% |
| Boundless Bio, Inc. Common Stock | -21.51 Million USD | -44.628% |
| Cara Therapeutics, Inc. | -9.01 Million USD | -245.064% |
| Cytokinetics, Incorporated | 642.37 Million USD | 104.843% |
| enGene Holdings Inc. Common Stock | -71.74 Million USD | 56.635% |
| Innoviva, Inc. | 255.56 Million USD | 112.174% |
| Hoth Therapeutics, Inc. | -9.23 Million USD | -236.802% |
| NLS Pharmaceutics AG | 736.06 Thousand USD | 4326.659% |
| RAPT Therapeutics, Inc. | -40.57 Million USD | 23.319% |
| Salarius Pharmaceuticals, Inc. | -5.61 Million USD | -454.537% |
| Terns Pharmaceuticals, Inc. | -79.32 Million USD | 60.779% |
| Vigil Neuroscience, Inc. | -38.14 Million USD | 18.434% |
| ImmuCell Corporation | 10.99 Million USD | 383.07% |
| IDEAYA Biosciences, Inc. | -154.14 Million USD | 79.817% |
| Incyte Corporation | -3.17 Billion USD | 99.02% |
| Inovio Pharmaceuticals, Inc. | 15.89 Million USD | 295.687% |
| Lexaria Bioscience Corp. | -1.18 Million USD | -2518.473% |
| Mustang Bio, Inc. | -3.73 Million USD | -732.736% |
| MiMedx Group, Inc. | -33.9 Million USD | 8.23% |
| MEI Pharma, Inc. | -3.7 Million USD | -739.703% |
| MacroGenics, Inc. | -66.98 Million USD | 53.555% |
| Monopar Therapeutics Inc. | -7.26 Million USD | -328.168% |
| Mereo BioPharma Group plc | -51.46 Million USD | 39.554% |
| Marker Therapeutics, Inc. | -15.11 Million USD | -105.877% |
| Marinus Pharmaceuticals, Inc. | -10.21 Million USD | -204.592% |
| Maravai LifeSciences Holdings, Inc. | 36 Million USD | 186.407% |
| Minerva Neurosciences, Inc. | 41 Million USD | 175.873% |
| NeuroBo Pharmaceuticals, Inc. | -22.23 Million USD | -39.938% |
| NeuroSense Therapeutics Ltd. | -2.53 Million USD | -1125.808% |
| NextCure, Inc. | -6.47 Million USD | -380.33% |
| Orchestra BioMed Holdings, Inc. | -28.87 Million USD | -7.755% |
| Ocuphire Pharma, Inc. | -50.5 Million USD | 38.395% |
| Onconetix, Inc. | 5.33 Million USD | 683.539% |
| Oncternal Therapeutics, Inc. | -6.37 Million USD | -387.71% |
| Opthea Limited | 28.15 Million USD | 210.489% |
| Ovid Therapeutics Inc. | 18.96 Million USD | 264.086% |
| Psyence Biomedical Ltd. | 6.89 Million USD | 551.237% |
| PDS Biotechnology Corporation | -32.7 Million USD | 4.885% |
| Precigen, Inc. | -481 Thousand USD | -6367.983% |
| Pieris Pharmaceuticals, Inc. | -17.39 Million USD | -78.84% |
| Prime Medicine, Inc. | -27.94 Million USD | -11.345% |
| PureTech Health plc | -167.19 Million USD | 81.393% |
| Rocket Pharmaceuticals, Inc. | -30.86 Million USD | -0.807% |
| Regeneron Pharmaceuticals, Inc. | -27.1 Million USD | -14.801% |
| Replimune Group, Inc. | 1.41 Million USD | 2303.329% |
| Revelation Biosciences, Inc. | -11.99 Million USD | -159.438% |
| Rigel Pharmaceuticals, Inc. | 27.79 Million USD | 211.938% |
| TransCode Therapeutics, Inc. | -2.31 Million USD | -1242.712% |
| Revolution Medicines, Inc. Warrant | -608.2 Million USD | 94.885% |
| Reviva Pharmaceuticals Holdings, Inc. | -18.51 Million USD | -67.987% |
| Sesen Bio, Inc. | -112.55 Million USD | 72.359% |
| Sangamo Therapeutics, Inc. | -7.1 Million USD | -338.183% |
| Solid Biosciences Inc. | -47.75 Million USD | 34.846% |
| Syndax Pharmaceuticals, Inc. | -293.75 Million USD | 89.409% |
| SciSparc Ltd. | -2.06 Million USD | -1406.586% |
| Sutro Biopharma, Inc. | 113.48 Million USD | 127.415% |
| TG Therapeutics, Inc. | 17.86 Million USD | 274.174% |
| Tonix Pharmaceuticals Holding Corp. | -15.13 Million USD | -105.557% |
| Titan Pharmaceuticals, Inc. | -6.2 Million USD | -401.144% |
| Travere Therapeutics, Inc. | 346.6 Million USD | 108.976% |
| UroGen Pharma Ltd. | 4.39 Million USD | 808.517% |
| Verrica Pharmaceuticals Inc. | -24.03 Million USD | -29.43% |
| XOMA Corporation | -29 Million USD | -7.279% |
| Zentalis Pharmaceuticals, Inc. | 17.73 Million USD | 275.421% |
| AbCellera Biologics Inc. | -55.94 Million USD | 44.385% |
| Longboard Pharmaceuticals, Inc. | -13.85 Million USD | -124.531% |
| Cassava Sciences, Inc. | -121.13 Million USD | 74.317% |
| Corbus Pharmaceuticals Holdings, Inc. | 6.96 Million USD | 546.479% |
| Precision BioSciences, Inc. | -85.41 Million USD | 63.575% |
| Dyadic International, Inc. | -6.37 Million USD | -387.779% |
| Intensity Therapeutics, Inc. | -8.39 Million USD | -270.457% |
| Eton Pharmaceuticals, Inc. | -15.93 Million USD | -95.261% |
| VYNE Therapeutics Inc. | -30.46 Million USD | -2.137% |
| Tenaya Therapeutics, Inc. | -33.25 Million USD | 6.453% |
| IGM Biosciences, Inc. | -72.6 Million USD | 57.151% |
| X4 Pharmaceuticals, Inc. | -41.18 Million USD | 24.46% |
| Acelyrin, Inc. | -216.9 Million USD | 85.657% |
| Abeona Therapeutics Inc. | -9.07 Million USD | -242.897% |
| Ligand Pharmaceuticals Incorporated | -16.78 Million USD | -85.306% |
| Inhibikase Therapeutics, Inc. | -8.54 Million USD | -264.162% |
| Arcturus Therapeutics Holdings Inc. | -316.78 Million USD | 90.179% |
| Syros Pharmaceuticals, Inc. | -77.45 Million USD | 59.831% |
| Senti Biosciences, Inc. | 1.74 Million USD | 1887.989% |
| Mesoblast Limited | 55.96 Million USD | 155.592% |
| Kymera Therapeutics, Inc. | -25.29 Million USD | -23.007% |
| ChromaDex Corporation | -24.04 Million USD | -29.37% |
| BriaCell Therapeutics Corp. | -862.08 Thousand USD | -3508.792% |
| Akebia Therapeutics, Inc. | 61.25 Million USD | 150.788% |
| Dermata Therapeutics, Inc. | -7.43 Million USD | -318.263% |
| Seer, Inc. | -4.24 Million USD | -633.75% |
| Xeris Biopharma Holdings, Inc. | 161.74 Million USD | 119.235% |
| Novavax, Inc. | -298.29 Million USD | 89.57% |
| Virpax Pharmaceuticals, Inc. | -9.14 Million USD | -240.327% |
| Fate Therapeutics, Inc. | 61.66 Million USD | 150.451% |
| Checkpoint Therapeutics, Inc. | -4.92 Million USD | -531.311% |
| Lyell Immunopharma, Inc. | -82.48 Million USD | 62.281% |
| Celcuity Inc. | 6.78 Million USD | 558.627% |
| ContextLogic Inc. | -232 Million USD | 86.59% |
| Phathom Pharmaceuticals, Inc. | -242.36 Million USD | 87.163% |
| HOOKIPA Pharma Inc. | -110.53 Million USD | 71.855% |
| Jazz Pharmaceuticals plc | 4.59 Billion USD | 100.678% |
| Amarin Corporation plc | -191.04 Million USD | 83.715% |
| AnaptysBio, Inc. | -18.15 Million USD | -71.401% |
| Aptevo Therapeutics Inc. | -11.5 Million USD | -170.366% |
| Aptorum Group Limited | 1.35 Million USD | 2392.553% |
| Cartesian Therapeutics, Inc. | -65.95 Million USD | 52.831% |
| Arrowhead Pharmaceuticals, Inc. | 4.28 Million USD | 826.893% |
| Ardelyx, Inc. | 34.51 Million USD | 190.145% |
| Celularity Inc. | 65.19 Million USD | 147.724% |
| Omeros Corporation | 331.17 Million USD | 109.394% |
| Humacyte, Inc. | -22.48 Million USD | -38.357% |
| Immunocore Holdings plc | -358.59 Million USD | 91.324% |
| IO Biotech, Inc. | -140.69 Million USD | 77.888% |
| GT Biopharma, Inc. | -1.02 Million USD | -2947.111% |
| Cabaletta Bio, Inc. | -188.22 Million USD | 83.471% |
| Summit Therapeutics Inc. | 34.67 Million USD | 189.724% |
| Alaunos Therapeutics, Inc. | -6.06 Million USD | -413.213% |
| Pulmatrix, Inc. | -10.41 Million USD | -198.656% |
| Intellia Therapeutics, Inc. | -111.4 Million USD | 72.073% |
| Evogene Ltd. | -19.63 Million USD | -58.455% |
| CorMedix Inc. | -43.05 Million USD | 27.737% |
| BioLineRx Ltd. | 7.33 Million USD | 524.087% |
| VistaGen Therapeutics, Inc. | -117.04 Million USD | 73.42% |
| Sagimet Biosciences Inc. | -75.07 Million USD | 58.56% |
| PTC Therapeutics, Inc. | -178.97 Million USD | 82.617% |
| scPharmaceuticals Inc. | -6.54 Million USD | -375.34% |
| Fulcrum Therapeutics, Inc. | -14.74 Million USD | -111.036% |
| Corcept Therapeutics Incorporated | -135.4 Million USD | 77.023% |
| NLS Pharmaceutics AG | 736.06 Thousand USD | 4326.659% |
| Reviva Pharmaceuticals Holdings, Inc. | -18.51 Million USD | -67.987% |
| Akero Therapeutics, Inc. | -208.16 Million USD | 85.055% |
| Eliem Therapeutics, Inc. | -92.76 Million USD | 66.462% |
| Lisata Therapeutics, Inc. | -22.28 Million USD | -39.586% |
| Stoke Therapeutics, Inc. | -184.6 Million USD | 83.147% |
| Reneo Pharmaceuticals, Inc. | -26.65 Million USD | -16.7% |
| Outlook Therapeutics, Inc. | 12.16 Million USD | 355.778% |
| ProMIS Neurosciences, Inc. | -16.69 Million USD | -86.381% |
| Daré Bioscience, Inc. | -5.15 Million USD | -503.171% |
| bluebird bio, Inc. | 108.57 Million USD | 128.655% |
| BioMarin Pharmaceutical Inc. | 378.74 Million USD | 108.214% |
| DBV Technologies S.A. | -126.98 Million USD | 75.5% |
| Avidity Biosciences, Inc. | -175.23 Million USD | 82.246% |
| Galecto, Inc. | -21.21 Million USD | -46.639% |
| Sensei Biotherapeutics, Inc. | -6.8 Million USD | -357.313% |
| Spruce Biosciences, Inc. | -91.73 Million USD | 66.084% |
| Inhibrx Biosciences, Inc. | -67.78 Million USD | 54.102% |
| GlycoMimetics, Inc. | -40.98 Million USD | 24.091% |
| Arcutis Biotherapeutics, Inc. | 116.59 Million USD | 126.683% |
| ADMA Biologics, Inc. | 90.06 Million USD | 134.542% |
| Clene Inc. | 3.34 Million USD | 1031.467% |
| Recursion Pharmaceuticals, Inc. | -344.12 Million USD | 90.959% |
| Aptose Biosciences Inc. | -8.19 Million USD | -279.641% |
| ZyVersa Therapeutics, Inc. | -3.12 Million USD | -894.274% |
| Soligenix, Inc. | -4.95 Million USD | -528.302% |
| Century Therapeutics, Inc. | 847 Thousand USD | 3773.081% |
| Kura Oncology, Inc. | -20.11 Million USD | -54.643% |
| Surrozen, Inc. | -32.66 Million USD | 4.754% |
| TScan Therapeutics, Inc. | -40.92 Million USD | 23.982% |
| Ocean Biomedical, Inc. | 1.82 Million USD | 1807.805% |
| CytomX Therapeutics, Inc. | -3.19 Million USD | -873.131% |
| Autolus Therapeutics plc | -186.59 Million USD | 83.327% |
| Mineralys Therapeutics, Inc. | -49.3 Million USD | 36.9% |
| Eterna Therapeutics Inc. | 34.26 Million USD | 190.787% |
| Caribou Biosciences, Inc. | -23.67 Million USD | -31.398% |
| GRI Bio, Inc. | -1.79 Million USD | -1634.169% |
| Xenetic Biosciences, Inc. | -8.98 Million USD | -246.33% |
| Janux Therapeutics, Inc. | 5.33 Million USD | 682.93% |
| INmune Bio, Inc. | -25.41 Million USD | -22.431% |
| Heron Therapeutics, Inc. | 150.95 Million USD | 120.61% |
| SAB Biotherapeutics, Inc. | -50.65 Million USD | 38.587% |
| Pasithea Therapeutics Corp. | -16.24 Million USD | -91.46% |
| Tenax Therapeutics, Inc. | -9.29 Million USD | -234.843% |
| Jaguar Health, Inc. | 29.39 Million USD | 205.852% |
| Entero Therapeutics, Inc. | -2.88 Million USD | -978.399% |
| Milestone Pharmaceuticals Inc. | 38.01 Million USD | 181.839% |
| Clearside Biomedical, Inc. | 14.08 Million USD | 320.943% |
| Atara Biotherapeutics, Inc. | 31.88 Million USD | 197.573% |
| Coherus BioSciences, Inc. | 377.95 Million USD | 108.231% |
| Verastem, Inc. | -37.27 Million USD | 16.543% |
| Pliant Therapeutics, Inc. | -51.86 Million USD | 40.012% |
| Histogen Inc. | -7.48 Million USD | -315.534% |
| Aprea Therapeutics, Inc. | -21.6 Million USD | -43.987% |
| ACADIA Pharmaceuticals Inc. | -131.45 Million USD | 76.333% |
| Surrozen, Inc. | -32.66 Million USD | 4.754% |
| Organovo Holdings, Inc. | -1.5 Million USD | -1964.433% |
| Lixte Biotechnology Holdings, Inc. | -4.2 Million USD | -640.123% |
| Cadrenal Therapeutics, Inc. Common Stock | -8.38 Million USD | -271.202% |
| Centessa Pharmaceuticals plc | -43.44 Million USD | 28.385% |
| Hepion Pharmaceuticals, Inc. | -14.57 Million USD | -113.427% |
| BioRestorative Therapies, Inc. | -722.06 Thousand USD | -4208.645% |
| Kronos Bio, Inc. | -36.05 Million USD | 13.71% |
| Turnstone Biologics Corp. | -14.58 Million USD | -113.323% |
| Synaptogenix, Inc. | -28.66 Million USD | -8.546% |
| Tiziana Life Sciences Ltd | -936 Thousand USD | -3223.825% |
| Entrada Therapeutics, Inc. | 628 Thousand USD | 5053.981% |
| Aurinia Pharmaceuticals Inc. | 48.73 Million USD | 163.841% |
| Exelixis, Inc. | -73.05 Million USD | 57.411% |
| Nurix Therapeutics, Inc. | -24.01 Million USD | -29.559% |
| Apellis Pharmaceuticals, Inc. | -241.37 Million USD | 87.111% |
| Jasper Therapeutics, Inc. | -84.1 Million USD | 63.008% |
| ESSA Pharma Inc. | -33.62 Million USD | 7.467% |
| TNF Pharmaceuticals, Inc. | -2.63 Million USD | -1081.966% |
| Avid Bioservices, Inc. | 169.72 Million USD | 118.33% |
| Insmed Incorporated | 721.62 Million USD | 104.311% |
| MediWound Ltd. | -5.32 Million USD | -484.573% |
| OmniAb, Inc. | 9.2 Million USD | 438.053% |
| Alector, Inc. | -35.63 Million USD | 12.7% |
| Seres Therapeutics, Inc. | 85.97 Million USD | 136.188% |
| Zai Lab Limited | -775 Million USD | 95.986% |
| AlloVir, Inc. | -62.69 Million USD | 50.375% |
| Revance Therapeutics, Inc. | 340.55 Million USD | 109.135% |
| ORIC Pharmaceuticals, Inc. | -13.17 Million USD | -136.208% |
| Aura Biosciences, Inc. | -21.52 Million USD | -44.534% |
| Immunic, Inc. | -45.34 Million USD | 31.383% |
| Tarsus Pharmaceuticals, Inc. | -193.21 Million USD | 83.898% |
| Veracyte, Inc. | -203.82 Million USD | 84.736% |
| InMed Pharmaceuticals Inc. | 638.29 Million USD | 104.874% |
| FibroGen, Inc. | 56.76 Million USD | 154.805% |
| SeaStar Medical Holding Corporation | 8.9 Million USD | 449.366% |
| Catalyst Pharmaceuticals, Inc. | -134.07 Million USD | 76.797% |
| Adial Pharmaceuticals, Inc. | -2.82 Million USD | -1000.463% |
| Sonnet BioTherapeutics Holdings, Inc. | -2.07 Million USD | -1402.694% |
| Cyclacel Pharmaceuticals, Inc. | -3.34 Million USD | -831.188% |
| Amylyx Pharmaceuticals, Inc. | -165.96 Million USD | 81.254% |
| Fortrea Holdings Inc. | 1.56 Billion USD | 101.982% |
| KalVista Pharmaceuticals, Inc. | -24.47 Million USD | -27.129% |
| XBiotech Inc. | -200.02 Million USD | 84.446% |
| Jasper Therapeutics, Inc. | -84.1 Million USD | 63.008% |
| Keros Therapeutics, Inc. | -316.7 Million USD | 90.177% |
| SELLAS Life Sciences Group, Inc. | -1.72 Million USD | -1704.582% |
| Lyra Therapeutics, Inc. | 4.52 Million USD | 787.08% |
| Foghorn Therapeutics Inc. | -35.26 Million USD | 11.774% |
| Agenus Inc. | 274.13 Million USD | 111.349% |
| Y-mAbs Therapeutics, Inc. | -77.21 Million USD | 59.71% |
| Theravance Biopharma, Inc. | 5.69 Million USD | 646.67% |
| Ultragenyx Pharmaceutical Inc. | -170.41 Million USD | 81.744% |
| Metagenomi, Inc. Common Stock | -92.37 Million USD | 66.321% |
| BioCryst Pharmaceuticals, Inc. | 736.26 Million USD | 104.226% |
| Gain Therapeutics, Inc. | -10.76 Million USD | -188.933% |
| C4 Therapeutics, Inc. | -55.61 Million USD | 44.059% |
| Creative Medical Technology Holdings, Inc. | -3.45 Million USD | -801.07% |
| Chemomab Therapeutics Ltd. | -8.97 Million USD | -246.6% |
| Lantern Pharma Inc. | -21.7 Million USD | -43.347% |
| Eledon Pharmaceuticals, Inc. | -4.22 Million USD | -635.659% |
| Ainos, Inc. | 4.07 Million USD | 862.912% |
| Pluri Inc. | 22.82 Million USD | 236.278% |
| Prothena Corporation plc | -608.34 Million USD | 94.886% |
| Adaptimmune Therapeutics plc | -118.75 Million USD | 73.803% |
| Rallybio Corporation | -24.1 Million USD | -29.081% |
| Kodiak Sciences Inc. | -103.87 Million USD | 70.05% |
| Cue Biopharma, Inc. | -33.81 Million USD | 8.007% |
| MeiraGTx Holdings plc | -40.3 Million USD | 22.805% |
| Annexon, Inc. | -193.75 Million USD | 83.943% |
| Assembly Biosciences, Inc. | -17.49 Million USD | -77.787% |
| Moderna, Inc. | -2.9 Billion USD | 98.93% |
| Cocrystal Pharma, Inc. | -24.57 Million USD | -26.596% |
| Cidara Therapeutics, Inc. | -30.9 Million USD | -0.68% |
| Blueprint Medicines Corporation | 702.83 Million USD | 104.426% |
| Immix Biopharma, Inc. | -17.5 Million USD | -77.678% |
| CalciMedica, Inc. | -5.53 Million USD | -462.586% |
| Monte Rosa Therapeutics, Inc. | -82.06 Million USD | 62.088% |
| Scholar Rock Holding Corporation | -40.03 Million USD | 22.294% |
| Wave Life Sciences Ltd. | -168.23 Million USD | 81.507% |
| Sana Biotechnology, Inc. | -33.25 Million USD | 6.442% |
| Elicio Therapeutics, Inc. | -5.97 Million USD | -420.512% |
| Adlai Nortye Ltd. American Depositary Shares | -59.94 Million USD | 48.1% |
| Nutriband Inc. | -251.65 Thousand USD | -12262.462% |
| Protara Therapeutics, Inc. | -34.11 Million USD | 8.816% |
| Vor Biopharma Inc. | 4.3 Million USD | 823.512% |
| Roivant Sciences Ltd. | -6.03 Billion USD | 99.485% |
| Alkermes plc | -166.73 Million USD | 81.341% |
| ProKidney Corp. | -56.23 Million USD | 44.678% |
| Applied Therapeutics, Inc. | -48.67 Million USD | 36.08% |
| Arcellx, Inc. | -296.95 Million USD | 89.523% |
| BridgeBio Pharma, Inc. | 1.36 Billion USD | 102.281% |
| Tango Therapeutics, Inc. | -27.46 Million USD | -13.275% |
| Galectin Therapeutics Inc. | 46.14 Million USD | 167.417% |
| Atai Life Sciences N.V. | -28.55 Million USD | -8.94% |
| Renovaro Biosciences Inc. | 2.23 Million USD | 1494.781% |
| Aerovate Therapeutics, Inc. | -22.81 Million USD | -36.356% |
| MediciNova, Inc. | -50.78 Million USD | 38.738% |
| Praxis Precision Medicines, Inc. | -78.8 Million USD | 60.522% |
| Cardio Diagnostics Holdings, Inc. | -22.49 Thousand USD | -138201.845% |
| GeoVax Labs, Inc. | -6.45 Million USD | -382.148% |
| Axsome Therapeutics, Inc. | -199.82 Million USD | 84.431% |
| Biomea Fusion, Inc. | -166.57 Million USD | 81.323% |
| RenovoRx, Inc. | -1.17 Million USD | -2552.259% |
| Cullinan Oncology, Inc. | -94.84 Million USD | 67.198% |
| Geron Corporation | 14.76 Million USD | 310.765% |
| NRx Pharmaceuticals, Inc. | 4.56 Million USD | 781.362% |
| 4D Molecular Therapeutics, Inc. | -234.43 Million USD | 86.729% |
| Dyne Therapeutics, Inc. | -94.21 Million USD | 66.977% |
| Kiniksa Pharmaceuticals, Ltd. | -95.69 Million USD | 67.49% |
| Royalty Pharma plc | 5.65 Billion USD | 100.55% |
| Ventyx Biosciences, Inc. | -39.07 Million USD | 20.377% |
| Imunon, Inc. | -4.21 Million USD | -638.303% |
| BioAtla, Inc. | -109.01 Million USD | 71.461% |
| Allogene Therapeutics, Inc. | 11.96 Million USD | 359.995% |
| Larimar Therapeutics, Inc. | -21.2 Million USD | -46.729% |
| Mersana Therapeutics, Inc. | -140.73 Million USD | 77.893% |
| Structure Therapeutics Inc. | -124.33 Million USD | 74.979% |
| 89bio, Inc. | -289.05 Million USD | 89.237% |
| Kezar Life Sciences, Inc. | -16.56 Million USD | -87.868% |
| aTyr Pharma, Inc. | -7.44 Million USD | -317.653% |
| Aligos Therapeutics, Inc. | -124.63 Million USD | 75.039% |
| Viridian Therapeutics, Inc. | -81.77 Million USD | 61.957% |
| EyeGate Pharmaceuticals, Inc. | -859.18 Thousand USD | -3520.994% |
| Akari Therapeutics, Plc | -3.84 Million USD | -709.129% |
| Tevogen Bio Holdings Inc. | 1.62 Million USD | 2017.012% |
| Halozyme Therapeutics, Inc. | 1.38 Billion USD | 102.253% |
| Lexicon Pharmaceuticals, Inc. | 83.59 Million USD | 137.215% |
| Liquidia Corporation | -80.17 Million USD | 61.197% |
| Entera Bio Ltd. | -10.62 Million USD | -192.699% |
| GH Research PLC | -78.07 Million USD | 60.153% |
| Vericel Corporation | 1.27 Million USD | 2536.257% |
| Arbutus Biopharma Corporation | -17.56 Million USD | -77.129% |
| Xencor, Inc. | 29.64 Million USD | 204.949% |
| 60 Degrees Pharmaceuticals, Inc. | -1.96 Million USD | -1479.389% |
| Pasithea Therapeutics Corp. | -16.24 Million USD | -91.46% |
| Coeptis Therapeutics Holdings, Inc. | -244.9 Thousand USD | -12603.138% |
| Vaxcyte, Inc. | -368.22 Million USD | 91.551% |
| Xenon Pharmaceuticals Inc. | -137.74 Million USD | 77.413% |
| Vanda Pharmaceuticals Inc. | -126.41 Million USD | 75.39% |
| Lexaria Bioscience Corp. | -1.18 Million USD | -2518.473% |
| Portage Biotech Inc. | -4.98 Million USD | -524.593% |
| Cardio Diagnostics Holdings, Inc. | -22.49 Thousand USD | -138201.845% |
| Olema Pharmaceuticals, Inc. | -66.12 Million USD | 52.949% |
| OncoCyte Corporation | -6.56 Million USD | -374.036% |
| Qualigen Therapeutics, Inc. | 897.41 Thousand USD | 3566.743% |
| Processa Pharmaceuticals, Inc. | -4.55 Million USD | -582.911% |
| Purple Biotech Ltd. | -14.13 Million USD | -120.052% |
| Tempest Therapeutics, Inc. | -18.56 Million USD | -67.543% |
| Sol-Gel Technologies Ltd. | -5.86 Million USD | -430.904% |
| Rhythm Pharmaceuticals, Inc. | -58.82 Million USD | 47.109% |
| CollPlant Biotechnologies Ltd. | -23.75 Million USD | -30.961% |
| Moleculin Biotech, Inc. | -22.97 Million USD | -35.407% |
| United Therapeutics Corporation | -507.7 Million USD | 93.872% |
| HilleVax, Inc. | -165.48 Million USD | 81.2% |
| Silo Pharma, Inc. | -3.52 Million USD | -782.755% |
| Telomir Pharmaceuticals, Inc. Common Stock | 99.76 Thousand USD | 31283.033% |
| Pharming Group N.V. | 109.8 Million USD | 128.333% |
| Tharimmune, Inc. | -10.93 Million USD | -184.499% |
| Genprex, Inc. | -6.73 Million USD | -361.75% |
| Apogee Therapeutics, Inc. | -116.28 Million USD | 73.245% |
| Neumora Therapeutics, Inc. Common Stock | -368.8 Million USD | 91.564% |
| Pyxis Oncology, Inc. | 10.19 Million USD | 405.159% |
| XTL Biopharmaceuticals Ltd. | -1.4 Million USD | -2120.628% |
| Virios Therapeutics, Inc. | -3.31 Million USD | -837.941% |
| OKYO Pharma Limited | -826.84 Thousand USD | -3662.602% |
| Savara Inc. | 153 Thousand USD | 20433.987% |
| Windtree Therapeutics, Inc. | 12.51 Million USD | 348.669% |
| Curis, Inc. | -23.88 Million USD | -30.242% |
| Carmell Therapeutics Corporation | -776.01 Thousand USD | -3909.087% |
| Achieve Life Sciences, Inc. | 1.18 Million USD | 2725.401% |
| BeiGene, Ltd. | -2.25 Billion USD | 98.619% |
| Protagonist Therapeutics, Inc. | -185.58 Million USD | 83.236% |
| Erasca, Inc. | -37.21 Million USD | 16.404% |
| Protagenic Therapeutics, Inc. | -1.28 Million USD | -2315.651% |
| Protagenic Therapeutics, Inc. | -1.28 Million USD | -2315.651% |
| Vincerx Pharma, Inc. | -10.35 Million USD | -200.531% |
| Fresh Tracks Therapeutics, Inc. | -10.86 Million USD | -186.262% |
| Acrivon Therapeutics, Inc. Common Stock | -31.37 Million USD | 0.829% |
| Celldex Therapeutics, Inc. | -32.27 Million USD | 3.598% |
| Cogent Biosciences, Inc. | -34.37 Million USD | 9.498% |
| Adicet Bio, Inc. | -138.78 Million USD | 77.584% |
| Amicus Therapeutics, Inc. | 198.06 Million USD | 115.707% |
| Aditxt, Inc. | 18.12 Million USD | 271.686% |
| Adagene Inc. | -87.62 Million USD | 64.496% |
| Estrella Immunopharma, Inc. | -4.16 Million USD | -646.886% |
| Quantum-Si incorporated | -118.55 Million USD | 73.759% |
| Acurx Pharmaceuticals, Inc. | -7.47 Million USD | -316.246% |
| Voyager Therapeutics, Inc. | -48.5 Million USD | 35.866% |
| Compugen Ltd. | -12.9 Million USD | -141.096% |
| Generation Bio Co. | 31.44 Million USD | 198.928% |
| Astria Therapeutics, Inc. | -175.36 Million USD | 82.259% |
| Black Diamond Therapeutics, Inc. | -30.92 Million USD | -0.608% |
| Invivyd, Inc. | -198.47 Million USD | 84.325% |
| Relay Therapeutics, Inc. | -90.27 Million USD | 65.536% |
| Quoin Pharmaceuticals, Ltd. | -2.39 Million USD | -1197.541% |
| Spero Therapeutics, Inc. | -70.79 Million USD | 56.052% |
| Artelo Biosciences, Inc. | -6.82 Million USD | -355.839% |
| 2seventy bio, Inc. | 181.71 Million USD | 117.121% |
| Instil Bio, Inc. | 75.35 Million USD | 141.284% |
| Capricor Therapeutics, Inc. | -9.08 Million USD | -242.53% |
| Elevai Labs, Inc. Common Stock | -3.11 Million USD | -898.311% |
| GeoVax Labs, Inc. | -6.45 Million USD | -382.148% |
| Citius Pharmaceuticals, Inc. | -25.99 Million USD | -19.659% |
| Relmada Therapeutics, Inc. | -4.09 Million USD | -660.369% |
| ALX Oncology Holdings Inc. | -5.2 Million USD | -497.255% |
| Vir Biotechnology, Inc. | -130.3 Million USD | 76.124% |
| Evaxion Biotech A/S | 5.28 Million USD | 688.461% |
| Ocular Therapeutix, Inc. | -112.56 Million USD | 72.362% |
| Verve Therapeutics, Inc. | -131.27 Million USD | 76.301% |
| Tyra Biosciences, Inc. | -51.51 Million USD | 39.602% |
| Cingulate Inc. | 3.08 Million USD | 1109.218% |
| Galmed Pharmaceuticals Ltd. | -2.93 Million USD | -959.278% |
| Unity Biotechnology, Inc. | 7.18 Million USD | 532.879% |
| Connect Biopharma Holdings Limited | -105.54 Million USD | 70.523% |
| Clearmind Medicine Inc. | -3.94 Million USD | -689.091% |
| Bolt Biotherapeutics, Inc. | 9.4 Million USD | 430.652% |
| CERo Therapeutics Holdings, Inc. | 1.45 Million USD | 2233.628% |
| Viking Therapeutics, Inc. | -54.25 Million USD | 42.659% |
| Madrigal Pharmaceuticals, Inc. | 17.27 Million USD | 280.061% |
| ImmunityBio, Inc. | 618.22 Million USD | 105.032% |
| Korro Bio, Inc. | -132.94 Million USD | 76.598% |
| Kineta, Inc. | -4.54 Million USD | -585.113% |
| BioVie Inc. | -17.73 Million USD | -75.448% |
| Codexis, Inc. | -43.27 Million USD | 28.102% |
| Celularity Inc. | 65.19 Million USD | 147.724% |
| Aileron Therapeutics, Inc. | 74.12 Million USD | 141.974% |
| Crinetics Pharmaceuticals, Inc. | -3.16 Million USD | -881.729% |
| Virax Biolabs Group Limited | -3.36 Million USD | -824.562% |
| Cibus, Inc. | -8.07 Million USD | -285.132% |
| IN8bio, Inc. | -16.38 Million USD | -89.829% |
| Adverum Biotechnologies, Inc. | 36 Thousand USD | 86519.444% |
| Avalo Therapeutics, Inc. | -3.51 Million USD | -785.596% |
| Ionis Pharmaceuticals, Inc. | 1.05 Billion USD | 102.951% |
| Eyenovia, Inc. | 1.25 Million USD | 2571.673% |
| Puma Biotechnology, Inc. | 26.9 Million USD | 215.633% |
| Conduit Pharmaceuticals Inc. | -3.24 Million USD | -859.328% |
| Elevation Oncology, Inc. | -19.11 Million USD | -62.731% |
| Xilio Therapeutics, Inc. | -33.24 Million USD | 6.425% |
| Cardiff Oncology, Inc. | -19.5 Million USD | -59.495% |
| Enanta Pharmaceuticals, Inc. | -58.87 Million USD | 47.158% |
| Regulus Therapeutics Inc. | -20.72 Million USD | -50.099% |
| Moolec Science SA | 117.61 Thousand USD | 26551.333% |
| Acumen Pharmaceuticals, Inc. | -38.39 Million USD | 18.98% |
| LAVA Therapeutics N.V. | -37.91 Million USD | 17.952% |
| Atea Pharmaceuticals, Inc. | -141.42 Million USD | 78.001% |
| Compass Therapeutics, Inc. | -22.49 Million USD | -38.302% |
| Greenwich LifeSciences, Inc. | -6.98 Million USD | -345.115% |
| TFF Pharmaceuticals, Inc. | -5.36 Million USD | -480.12% |
| Humacyte, Inc. | -22.48 Million USD | -38.357% |
| PMV Pharmaceuticals, Inc. | -25.24 Million USD | -23.251% |
| Avenue Therapeutics, Inc. | -1.78 Million USD | -1644.868% |
| Genelux Corporation | -6.89 Million USD | -350.949% |
| Trevi Therapeutics, Inc. | -31.05 Million USD | -0.167% |
| Notable Labs, Ltd. | -9.77 Million USD | -218.239% |
| Immunovant, Inc. | -635.22 Million USD | 95.102% |
| Quantum-Si incorporated | -118.55 Million USD | 73.759% |
| DiaMedica Therapeutics Inc. | -4.14 Million USD | -650.929% |
| Vera Therapeutics, Inc. | 8.02 Million USD | 487.579% |
| Acasti Pharma Inc. | -23 Million USD | -35.236% |
| MiNK Therapeutics, Inc. | -3.36 Million USD | -823.935% |
| Soleno Therapeutics, Inc. | -169.27 Million USD | 81.621% |
| PepGen Inc. | -60.67 Million USD | 48.721% |
| Nuvectis Pharma, Inc. | -19.12 Million USD | -62.663% |
| BriaCell Therapeutics Corp. | -862.08 Thousand USD | -3508.792% |
| Immuneering Corporation | -54.94 Million USD | 43.376% |
| Lixte Biotechnology Holdings, Inc. | -4.2 Million USD | -640.123% |
| Belite Bio, Inc | -87.27 Million USD | 64.351% |
| XOMA Corporation | -29 Million USD | -7.279% |
| ARS Pharmaceuticals, Inc. | -70.69 Million USD | 55.994% |
| Bionomics Limited | 227 Million USD | 113.705% |
| Alpha Tau Medical Ltd. | -2.53 Million USD | -1128.227% |
| uniQure N.V. | -102.95 Million USD | 69.781% |
| Estrella Immunopharma, Inc. | -4.16 Million USD | -646.886% |
| Poseida Therapeutics, Inc. | 40.95 Million USD | 175.971% |
| Forte Biosciences, Inc. | -11.96 Million USD | -160.104% |
| Anebulo Pharmaceuticals, Inc. | -3.09 Million USD | -905.462% |
| Enlivex Therapeutics Ltd. | 106 Thousand USD | 29450.0% |
| Conduit Pharmaceuticals Inc. | -3.24 Million USD | -859.328% |
| SeaStar Medical Holding Corporation | 8.9 Million USD | 449.366% |
| FibroBiologics, Inc. Common Stock | -7.41 Million USD | -319.512% |
| Altimmune, Inc. | -134.48 Million USD | 76.867% |
| LENZ Therapeutics, Inc. | -185.49 Million USD | 83.228% |
| Alpha Tau Medical Ltd. | -2.53 Million USD | -1128.227% |
| Peak Bio, Inc. | 10.34 Million USD | 400.875% |
| Zevra Therapeutics, Inc. | -283 Thousand USD | -10893.286% |
| Benitec Biopharma Inc. | -50.58 Million USD | 38.494% |
| Spyre Therapeutics, Inc. | -104.33 Million USD | 70.182% |
| NKGen Biotech, Inc. Common Stock | 19.64 Million USD | 258.366% |
| Zura Bio Limited | -99.8 Million USD | 68.829% |
| PolyPid Ltd. | 6.17 Million USD | 604.23% |
| NKGen Biotech, Inc. Warrants | 19.64 Million USD | 258.366% |
| argenx SE | -2.02 Billion USD | 98.467% |
| Immunome, Inc. | -97.02 Million USD | 67.936% |
| Verona Pharma plc | -220.44 Million USD | 85.887% |
| enGene Holdings Inc. Warrants | -71.74 Million USD | 56.635% |
| Shattuck Labs, Inc. | -121.42 Million USD | 74.378% |
| CervoMed Inc. | -7.79 Million USD | -299.225% |
| Plus Therapeutics, Inc. | -4.37 Million USD | -611.434% |
| Dianthus Therapeutics, Inc. | -131.73 Million USD | 76.385% |
| Moolec Science SA | 117.61 Thousand USD | 26551.333% |
| Enveric Biosciences, Inc. | -2.28 Million USD | -1259.76% |
| Design Therapeutics, Inc. | -18.15 Million USD | -71.41% |
| Leap Therapeutics, Inc. | -70.38 Million USD | 55.796% |
| Seelos Therapeutics, Inc. | 11.23 Million USD | 376.985% |
| Achilles Therapeutics plc | -126.92 Million USD | 75.488% |
| CERo Therapeutics Holdings, Inc. | 1.45 Million USD | 2233.628% |
| CG Oncology, Inc. Common stock | -7.44 Million USD | -318.159% |
| Fractyl Health, Inc. Common Stock | 340.19 Million USD | 109.145% |
| Rani Therapeutics Holdings, Inc. | 23.73 Million USD | 231.076% |
| MoonLake Immunotherapeutics | -447.47 Million USD | 93.047% |
| Tourmaline Bio, Inc. | -140.31 Million USD | 77.827% |
| Beam Therapeutics Inc. | -262.72 Million USD | 88.158% |
| Mirum Pharmaceuticals, Inc. | 21.81 Million USD | 242.606% |
| AEON Biopharma, Inc. | -4.88 Million USD | -537.52% |
| Aadi Bioscience, Inc. | -55.86 Million USD | 44.309% |
| Enliven Therapeutics, Inc. | -99.86 Million USD | 68.845% |
| Kiora Pharmaceuticals, Inc. | -2.34 Million USD | -1225.117% |
| NeurAxis, Inc. | 145.7 Thousand USD | 21452.78% |
| Iovance Biotherapeutics, Inc. | -39.02 Million USD | 20.281% |
| Lumos Pharma, Inc. | -28.49 Million USD | -9.188% |
| Opiant Pharmaceuticals, Inc. | -20.77 Million USD | -49.761% |
| Palisade Bio, Inc. | -12.06 Million USD | -157.904% |
| Nutriband Inc. | -251.65 Thousand USD | -12262.462% |
| Taysha Gene Therapies, Inc. | -83.28 Million USD | 62.644% |
| Neurogene Inc. | -131.95 Million USD | 76.423% |
| Kintara Therapeutics, Inc. | -4.9 Million USD | -533.754% |
| CARGO Therapeutics, Inc. Common Stock | -377.19 Million USD | 91.752% |
| Athira Pharma, Inc. | -88.99 Million USD | 65.043% |
| HCW Biologics Inc. | 2.85 Million USD | 1189.063% |
| XOMA Corporation | -29 Million USD | -7.279% |
| Nektar Therapeutics | 210.24 Million USD | 114.798% |
| Arvinas, Inc. | -313.8 Million USD | 90.086% |
| Tevogen Bio Holdings Inc. | 1.62 Million USD | 2017.012% |
| Merus N.V. | -192.88 Million USD | 83.871% |
| Omega Therapeutics, Inc. | 59.98 Million USD | 151.865% |
| Quince Therapeutics, Inc. | -6.93 Million USD | -348.415% |
| Rezolute, Inc. | -68.16 Million USD | 54.361% |
| Clene Inc. | 3.34 Million USD | 1031.467% |
| Indaptus Therapeutics, Inc. | -13.18 Million USD | -135.922% |
| BeyondSpring Inc. | -13.75 Million USD | -126.18% |
| Synlogic, Inc. | -6.68 Million USD | -365.385% |
| Allarity Therapeutics, Inc. | 1.13 Million USD | 2843.474% |
| Phio Pharmaceuticals Corp. | -8.45 Million USD | -267.96% |
| Peak Bio, Inc. | 10.34 Million USD | 400.875% |
| Werewolf Therapeutics, Inc. | -82.42 Million USD | 62.253% |
| Krystal Biotech, Inc. | -350.23 Million USD | 91.117% |
| Karyopharm Therapeutics Inc. | 124.12 Million USD | 125.064% |
| SpringWorks Therapeutics, Inc. | -168.99 Million USD | 81.591% |
| Lipella Pharmaceuticals Inc. | -3.15 Million USD | -885.416% |
| MannKind Corporation | 143.89 Million USD | 121.62% |
| Ikena Oncology, Inc. | -109.15 Million USD | 71.499% |
| Cyclerion Therapeutics, Inc. | -7.57 Million USD | -310.923% |
| Gyre Therapeutics, Inc. | -33.1 Million USD | 6.009% |
| Gossamer Bio, Inc. | 180.35 Million USD | 117.25% |
| CohBar, Inc. | -5.93 Million USD | -424.573% |
| Cognition Therapeutics, Inc. | -29.74 Million USD | -4.582% |
| NRx Pharmaceuticals, Inc. | 4.56 Million USD | 781.362% |
| Legend Biotech Corporation | -949.39 Million USD | 96.723% |
| Mural Oncology plc | -255.84 Million USD | 87.84% |
| Disc Medicine, Inc. | -358.28 Million USD | 91.317% |
| Champions Oncology, Inc. | 4.81 Million USD | 746.53% |
| REGENXBIO Inc. | 54.76 Million USD | 156.805% |
| Ensysce Biosciences, Inc. | -268.9 Thousand USD | -11469.427% |
| Anavex Life Sciences Corp. | -151.02 Million USD | 79.4% |
| Cellectar Biosciences, Inc. | -9.01 Million USD | -245.217% |
| Edgewise Therapeutics, Inc. | -80.68 Million USD | 61.44% |
| Vaxart, Inc. | -8.24 Million USD | -277.515% |
| PharmaCyte Biotech, Inc. | -50.17 Million USD | 38.001% |
| Aldeyra Therapeutics, Inc. | -127.16 Million USD | 75.535% |
| Cellectis S.A. | -43.85 Million USD | 29.059% |
| Longeveron Inc. | -2.9 Million USD | -969.842% |
| Repare Therapeutics Inc. | -107.85 Million USD | 71.156% |
| Sarepta Therapeutics, Inc. | 968.37 Million USD | 103.213% |
| Inozyme Pharma, Inc. | 12 Million USD | 359.172% |
| Revolution Medicines, Inc. | -608.2 Million USD | 94.885% |
| Nymox Pharmaceutical Corporation | -1.23 Million USD | -2429.35% |
| Third Harmonic Bio, Inc. | -265.11 Million USD | 88.265% |
| ArriVent BioPharma, Inc. Common Stock | -150.07 Million USD | 79.269% |
| AN2 Therapeutics, Inc. | -15.64 Million USD | -98.83% |
| Anixa Biosciences, Inc. | -740 Thousand USD | -4104.189% |
| Vertex Pharmaceuticals Incorporated | -9.56 Billion USD | 99.675% |
| Denali Therapeutics Inc. | -74.86 Million USD | 58.444% |
| Revelation Biosciences, Inc. | -11.99 Million USD | -159.438% |
| Veru Inc. | 4.77 Million USD | 750.862% |
| Corvus Pharmaceuticals, Inc. | -11.24 Million USD | -176.641% |
| Cingulate Inc. | 3.08 Million USD | 1109.218% |
| Passage Bio, Inc. | 4.58 Million USD | 778.539% |
| Context Therapeutics Inc. | -14.44 Million USD | -115.304% |
| Exicure, Inc. | 5.84 Million USD | 631.903% |
| Day One Biopharmaceuticals, Inc. | -230.37 Million USD | 86.496% |
| Oramed Pharmaceuticals Inc. | -39.57 Million USD | 21.377% |
| Scinai Immunotherapeutics Ltd. | 15.69 Million USD | 298.273% |
| Nuvalent, Inc. | -335.38 Million USD | 90.724% |
| ABVC BioPharma, Inc. | 1.73 Million USD | 1893.823% |
| Carisma Therapeutics, Inc. | -74.48 Million USD | 58.23% |
| Unicycive Therapeutics, Inc. | -8.89 Million USD | -249.955% |
| OmniAb, Inc. | 9.2 Million USD | 438.053% |
| Anew Medical, Inc. | 1.43 Million USD | 2271.851% |
| Fennec Pharmaceuticals Inc. | 16.38 Million USD | 289.912% |
| Lipocine Inc. | -4.75 Million USD | -554.336% |
| Lexeo Therapeutics, Inc. Common Stock | -109.82 Million USD | 71.673% |
| Nautilus Biotechnology, Inc. | 15.23 Million USD | 304.261% |
| SAB Biotherapeutics, Inc. | -50.65 Million USD | 38.587% |
| G1 Therapeutics, Inc. | 24.89 Million USD | 224.984% |
| Bellerophon Therapeutics, Inc. | -6.72 Million USD | -362.892% |
| Sage Therapeutics, Inc. | -65.82 Million USD | 52.738% |
| Ocugen, Inc. | -32.52 Million USD | 4.336% |
| Mind Medicine (MindMed) Inc. | -85.57 Million USD | 63.645% |
| Q32 Bio Inc. | -37.94 Million USD | 18.017% |
| Brainstorm Cell Therapeutics Inc. | -628 Thousand USD | -4853.981% |
| Alumis Inc. Common Stock | -13.52 Million USD | -129.958% |
| Equillium, Inc. | -22.39 Million USD | -38.938% |
| Kyverna Therapeutics, Inc. | -25.56 Million USD | -21.679% |
| Coya Therapeutics, Inc. | -32.62 Million USD | 4.646% |
| CNS Pharmaceuticals, Inc. | -247.91 Thousand USD | -12449.059% |
| Dominari Holdings Inc. | 195 Thousand USD | 16054.359% |
| Edesa Biotech, Inc. | -5.26 Million USD | -490.688% |
| vTv Therapeutics Inc. | -8.91 Million USD | -248.895% |
| Bio-Techne Corporation | 267.74 Million USD | 111.62% |
| Agios Pharmaceuticals, Inc. | -16.2 Million USD | -91.937% |
| Harmony Biosciences Holdings, Inc. | -118.09 Million USD | 73.656% |
| Prelude Therapeutics Incorporated | -8.4 Million USD | -270.237% |
| Candel Therapeutics, Inc. | -12.65 Million USD | -145.917% |
| iTeos Therapeutics, Inc. | -245.11 Million USD | 87.308% |
| Nkarta, Inc. | 57.29 Million USD | 154.296% |
| BioCardia, Inc. | 212 Thousand USD | 14775.0% |
| Iterum Therapeutics plc | 13.43 Million USD | 331.515% |